1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.43%
Net income growth of 11.43% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
11.97%
D&A growth of 11.97% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
346.29%
SBC growth of 346.29% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-4008.66%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
-185.95%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
-51723.06%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
100.00%
AP growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
117.15%
Growth of 117.15% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
187.28%
Growth of 187.28% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
48.20%
CFO growth of 48.20% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-5.66%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
93.95%
Growth of 93.95% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-2.87%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.